Technical Analysis for CRVS - Corvus Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 7.16% | |
| NR7 | Range Contraction | 7.16% | |
| NR7-2 | Range Contraction | 7.16% | |
| BB Squeeze Started | Range Contraction | 7.16% | |
| NR7 | Range Contraction | 5.12% | |
| NR7-2 | Range Contraction | 5.12% | |
| 20 DMA Resistance | Bearish | 5.88% | |
| NR7 | Range Contraction | 5.88% | |
| Fell Below 20 DMA | Bearish | 3.64% | |
| New Downtrend | Bearish | 3.64% |
| Alert | Time |
|---|---|
| Rose Above 20 DMA | 24 minutes ago |
| 20 DMA Resistance | 33 minutes ago |
| Rose Above 10 DMA | 42 minutes ago |
| 10 DMA Resistance | about 1 hour ago |
| Up 5% | about 1 hour ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/05/2024
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.0 |
| 52 Week Low | 1.3 |
| Average Volume | 811,036 |
| 200-Day Moving Average | 3.53 |
| 50-Day Moving Average | 7.07 |
| 20-Day Moving Average | 8.72 |
| 10-Day Moving Average | 8.71 |
| Average True Range | 0.72 |
| RSI (14) | 51.92 |
| ADX | 27.75 |
| +DI | 19.27 |
| -DI | 21.31 |
| Chandelier Exit (Long, 3 ATRs) | 7.85 |
| Chandelier Exit (Short, 3 ATRs) | 9.19 |
| Upper Bollinger Bands | 9.60 |
| Lower Bollinger Band | 7.84 |
| Percent B (%b) | 0.23 |
| BandWidth | 20.18 |
| MACD Line | 0.38 |
| MACD Signal Line | 0.60 |
| MACD Histogram | -0.2123 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.80 | ||||
| Resistance 3 (R3) | 8.78 | 8.59 | 8.70 | ||
| Resistance 2 (R2) | 8.59 | 8.45 | 8.59 | 8.67 | |
| Resistance 1 (R1) | 8.41 | 8.36 | 8.32 | 8.43 | 8.64 |
| Pivot Point | 8.22 | 8.22 | 8.17 | 8.22 | 8.22 |
| Support 1 (S1) | 8.04 | 8.08 | 7.95 | 8.06 | 7.84 |
| Support 2 (S2) | 7.85 | 7.99 | 7.85 | 7.81 | |
| Support 3 (S3) | 7.67 | 7.85 | 7.78 | ||
| Support 4 (S4) | 7.69 |
